Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glycolic acid review

This article was originally published in The Rose Sheet

Executive Summary

CTFA is asking the Cosmetic Ingredient Review (CIR) to hasten its consideration of the safety of glycolic acid because of FDA's concern regarding alpha hydroxy acids, particularly when used at high concentrations ("The Rose Sheet" April 11, p. 1). CTFA also is requesting that CIR look at the commonly used salts and esters of glycolic acid as well as citric and lactic acids and their salts and esters. CIR would have reviewed glycolic acid beginning in 1995

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel